Clinical Trial

Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan

Name: Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan — clinical trial record (NCT07704697)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 3

View on ClinicalTrials.gov →

Summary

The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Sacubitril/Allisartan (240mg).

Trial Details

NCT Number	NCT07704697
Lead Sponsor	Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions	Essential Hypertension
Enrollment	346 participants
Start Date	2024-11-23
Primary Completion	2025-11-10 (estimated)
Study Completion	2025-11-24 (estimated)
Updated on ClinicalTrials.gov	2026-07-15